Self-Reported Symptoms in a Cohort of Rheumatoid Arthritis and Systemic Lupus Erythematosus during the COVID-19 Quarantine Period

Table 3: Association of self-reported symptoms with the supply of hydroxychloroquine or methotrexate.

Diagnosis	Disease-modifying drug(s) prescribed	No. of Patients	Supply of Drug Analyzed	Symptoms	Drug Supply
Diagnosis	Disease-modifying drug(s) prescribed	No. of Patients	Supply of Drug Analyzed	Symptoms	Regular	Irregular	p-value
Systemic Lupus Erythematosus	Hydroxychloroquine	323	Hydroxychloroquine	Muscle pain	31 (27.9)	86 (40.6)	0.03
Systemic Lupus Erythematosus	Hydroxychloroquine	323	Hydroxychloroquine	Rash	13 (11.7)	58 (27.4)	<0.001
Rheumatoid Arthritis	Hydroxychloroquine	18	Hydroxychloroquine	Dizziness	2 (66.7)	0 (0.0)	<0.001
Rheumatoid Arthritis	Hydroxychloroquine and methotrexate	36	Methotrexate	Joint pain with or without swelling	5 (38.5)	17 (73.9)	0.04